How should we think about endocrine resistance in patients with inherited germline mutations such as BRCA, CHEK2, etc.?

In patients with germline mutations such as BRCA1/2, we have learned that the use of CDK4/6 inhibitors may have less of an impact, suggesting some degree of inherent endocrine therapy resistance. In one retrospective analysis of patients with germline mutations in homologous recombination repair (su...